ADVANCE AUTOLOGOUS
STEM CELL TECHNOLOGY

Autologous Stem Cell Technology (ASCT)

Founded in July 2011, Autologous Stem Cell Technology (ASCT) is a pioneering Australian biotech company dedicated to redefining regenerative medicine. We were the first globally to patent a revolutionary method of producing multi-lineage potential stem cells directly from adult white blood cells without any genetic manipulation. Our core breakthrough, Autologous Multilineage Potential Cells (AMPC), operates under official Australian Therapeutic Goods Administration (TGA) regulatory exemptions, ensuring a compliant pathway to advanced cellular therapy. With over 2,000 successful treatments administered for complex degenerative and autoimmune conditions, ASCT stands as a global leader in clinical safety and innovation. We remain the only stem cell provider in Australia backed by comprehensive Lloyd's of London insurance protection, boasting a perfect, claim-free safety record for over a decade.

Discover a breakthrough in cellular therapy. By transforming a simple sample of adult white blood cells into highly versatile, adaptable stem cells, we unlock the body's natural blueprint for deep tissue regeneration and healing.

(AMPC) are self-renewing stem cells dedifferentiated from adult white blood cells that possess the rare ability to transform into any of the body's three primary germ layers—including ectoderm (neurons), mesoderm (cardiac cells and osteoblasts), and endoderm (liver cells). What truly sets AMPCs apart is their inherent homing effect, which allows them to dynamically respond to the body's chemical signals, automatically navigate to damaged tissues, and prioritize those areas for cellular repair. This unconfined, versatile differentiation makes AMPCs highly effective across a massive therapeutic scope, offering advanced treatment options for various degenerative and autoimmune conditions such as arthritis, leukaemia, kidney failure, and cardiovascular diseases. Backed by comprehensive Lloyd's of London insurance protection for both patients and practitioners—with zero claims made to date—AMPCs represent a highly secure, targeted, and powerful frontier in regenerative medicine

When compared to traditional alternatives, Autologous Multilineage Potential Cells (AMPC) offer an unmatched combination of therapeutic power, safety, and patient comfort. Unlike embryonic (ESC) and induced pluripotent (iPSC) stem cells—which carry significant ethical concerns or cancer risks that currently render them unsuitable for human use—AMPCs provide a highly potent, ethical, and oncologically safe solution. Furthermore, while hematopoietic (HSC) and mesenchymal (MSC) stem cells are restricted to limited cell types and require invasive transplant surgeries or liposuction, AMPCs boast a high-yield, multilineage potential achieved entirely through simple, non-surgical intravenous collection and injection without the need for external donors.